Viatris Inc (VTRS)

$13.41 -0.03 (-0.22%)
Market Cap 15.47B
Revenue (ttm) 14.30B
Net Income (ttm) -3.51B
EPS (ttm) N/A
PE Ratio 5.78
Forward PE 5.57
Profit Margin -24.58%
Debt to Equity Ratio 1.12
Volume 8,617,500
Avg Vol 10,546,500
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 61%
Beta 0.83
Analysts Sell
Price Target $15.78

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
CapitalMonk
CapitalMonk Apr. 6 at 10:43 AM
$VTRS Price: $13.44 (-1.39%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.85% RSI: 48.6 | Momentum: Moderate Volume: -40.6% vs avg Volatility: 1.72% Support: $12.87 | Resistance: $14.52 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
ShirleyG
ShirleyG Mar. 29 at 3:57 AM
$VTRS ⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️
0 · Reply
erevnon
erevnon Mar. 24 at 2:48 PM
Barclays maintains Viatris $VTRS at Overweight and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 20 at 2:46 PM
$VTRS can come down to $12 and technically still be in the bullish path.
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 19 at 1:55 PM
$VTRS $16 to $13 in less than 3 weeks. and still falling like a rock.
0 · Reply
RunnerSignals
RunnerSignals Mar. 13 at 8:41 PM
$DG $TGT $KO $CTVA $VTRS price action showed controlled pullbacks and higher lows as money rotated toward stable earnings exposure https://stocksrunner.com/news/2026-03-13-top-stock-upgrades-today-in-the-buzz
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 13 at 8:15 PM
$VTRS hit the very top of the channel and bounced. will see where it goes from here but it should be due a small B wave bounce.
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 12 at 1:54 PM
$VTRS almost at the last support line that I can find as still see a bullish path for VTRS.
0 · Reply
StockConsultant
StockConsultant Mar. 10 at 1:27 PM
$VTRS Viatris stock watch, pulback to 14.14 support area
1 · Reply
DailyAnalysis
DailyAnalysis Mar. 6 at 4:59 PM
Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis
0 · Reply
Latest News on VTRS
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Mar 31, 2026, 7:51 AM EDT - 7 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS UNH

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Mar 23, 2026, 6:59 AM EDT - 15 days ago

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Mar 19, 2026, 8:30 AM EDT - 19 days ago

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

Mar 12, 2026, 11:11 AM EDT - 26 days ago

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

These S&P 500 stocks are falling the hardest on Tuesday

Mar 3, 2026, 10:41 AM EST - 5 weeks ago

These S&P 500 stocks are falling the hardest on Tuesday

ALB APO ARES BX CIEN FCX GEV

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

Feb 27, 2026, 1:03 PM EST - 5 weeks ago

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

DASH DPZ SJM

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Feb 26, 2026, 8:37 AM EST - 5 weeks ago

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 26, 2026, 6:59 AM EST - 5 weeks ago

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Feb 26, 2026, 6:55 AM EST - 5 weeks ago

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 5 weeks ago

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Feb 19, 2026, 9:02 AM EST - 6 weeks ago

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Feb 17, 2026, 7:46 AM EST - 7 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

CVS UNH

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Feb 3, 2026, 4:34 PM EST - 2 months ago

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Feb 3, 2026, 8:30 AM EST - 2 months ago

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Jan 20, 2026, 6:59 AM EST - 2 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

LXRX

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Jan 8, 2026, 9:05 AM EST - 3 months ago

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Jan 6, 2026, 9:00 AM EST - 3 months ago

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 18, 2025, 6:59 AM EST - 3 months ago

Viatris Provides Pipeline Update on Four Regulatory Milestones

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 6:59 AM EST - 3 months ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Dec 6, 2025, 9:00 AM EST - 4 months ago

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 4 months ago

Viatris to Participate in Upcoming Investor Conferences

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Nov 13, 2025, 8:00 AM EST - 5 months ago

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Nov 6, 2025, 8:16 AM EST - 5 months ago

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Nov 6, 2025, 6:59 AM EST - 5 months ago

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Viatris Announces Quarterly Dividend

Nov 4, 2025, 6:59 AM EST - 5 months ago

Viatris Announces Quarterly Dividend

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Oct 15, 2025, 4:30 PM EDT - 6 months ago

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Oct 8, 2025, 11:00 AM EDT - 6 months ago

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 1, 2025, 9:00 AM EDT - 6 months ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 19, 2025, 9:00 AM EDT - 8 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 11, 2025, 9:29 AM EDT - 8 months ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 9:36 AM EDT - 8 months ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 7, 2025, 6:59 AM EDT - 8 months ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 5, 2025, 6:55 AM EDT - 8 months ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Aug 1, 2025, 10:00 AM EDT - 8 months ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Jul 22, 2025, 11:19 AM EDT - 9 months ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Jul 18, 2025, 2:17 PM EDT - 9 months ago

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 8:47 AM EDT - 9 months ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 9 months ago

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 18, 2025, 6:59 AM EDT - 9 months ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 26, 2025, 6:55 AM EDT - 10 months ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 12, 2025, 4:30 PM EDT - 10 months ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Jun 2, 2025, 1:12 PM EDT - 11 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

May 31, 2025, 8:45 AM EDT - 11 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

CapitalMonk
CapitalMonk Apr. 6 at 10:43 AM
$VTRS Price: $13.44 (-1.39%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.85% RSI: 48.6 | Momentum: Moderate Volume: -40.6% vs avg Volatility: 1.72% Support: $12.87 | Resistance: $14.52 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
ShirleyG
ShirleyG Mar. 29 at 3:57 AM
$VTRS ⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️⬆️
0 · Reply
erevnon
erevnon Mar. 24 at 2:48 PM
Barclays maintains Viatris $VTRS at Overweight and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 20 at 2:46 PM
$VTRS can come down to $12 and technically still be in the bullish path.
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 19 at 1:55 PM
$VTRS $16 to $13 in less than 3 weeks. and still falling like a rock.
0 · Reply
RunnerSignals
RunnerSignals Mar. 13 at 8:41 PM
$DG $TGT $KO $CTVA $VTRS price action showed controlled pullbacks and higher lows as money rotated toward stable earnings exposure https://stocksrunner.com/news/2026-03-13-top-stock-upgrades-today-in-the-buzz
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 13 at 8:15 PM
$VTRS hit the very top of the channel and bounced. will see where it goes from here but it should be due a small B wave bounce.
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 12 at 1:54 PM
$VTRS almost at the last support line that I can find as still see a bullish path for VTRS.
0 · Reply
StockConsultant
StockConsultant Mar. 10 at 1:27 PM
$VTRS Viatris stock watch, pulback to 14.14 support area
1 · Reply
DailyAnalysis
DailyAnalysis Mar. 6 at 4:59 PM
Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 5 at 7:52 PM
$VTRS the last time VTRS was over $16 in 2022 it quickly dropped to around $10. I expect this drop to follow a very similar path.
1 · Reply
DailyAnalysis
DailyAnalysis Mar. 5 at 7:51 PM
Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Mar. 5 at 8:57 AM
Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 3 at 11:11 PM
$VTRS $15 disappeared just as quick as $16 did. I do not show any support down to $13.
2 · Reply
DailyAnalysis
DailyAnalysis Mar. 3 at 9:17 PM
Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis
0 · Reply
ItsCarRamRod
ItsCarRamRod Mar. 3 at 2:43 PM
$VTRS yesterdays gain obliterated in the first 15 minutes of trading.
0 · Reply
WallStJesus
WallStJesus Mar. 2 at 7:39 PM
$VTRS Put/Call: 174/4563
0 · Reply
DailyAnalysis
DailyAnalysis Mar. 2 at 6:45 PM
Despite weak guidance, $VTRS is hitting extreme 1D oversold levels. RSI and CCI suggest a 4H relief rally. Use 30M to time the bounce following the India facility news and restructuring plan. @DailyAnalysis
0 · Reply
LindaKhadra
LindaKhadra Mar. 2 at 6:33 AM
$VTRS JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating 6:02 AM ET, 02/27/2026 - MT Newswires
0 · Reply
LindaKhadra
LindaKhadra Mar. 2 at 6:32 AM
$VTRS Jefferies & Co Adjusts Viatris Price Target to $17 From $14, Maintains Buy Rating 7:21 AM ET, 02/27/2026 - MT Newswires
0 · Reply
LindaKhadra
LindaKhadra Mar. 2 at 6:31 AM
$VTRS Truist Securities Adjusts Price Target on Viatris to $18 From $16, Maintains Buy Rating 11:13 AM ET, 02/27/2026 - MT Newswires
0 · Reply
LindaKhadra
LindaKhadra Mar. 2 at 6:29 AM
$VTRS UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating 10:38:31 AM ET, 02/27/2026 - MT Newswires
0 · Reply